Myoblast-Based Cell Transplantation
Myoblast-Based Cell Transplantation
复制标题
成肌细胞细胞移植
作者：
P. Menasché
细胞移植作为一种新的治疗方法正在出现，旨在改善心力衰竭患者的不良结局。其基本原理是将收缩细胞植入梗死后瘢痕可以在功能上使这些区域恢复活力。首先由于实际原因，自体骨骼肌成肌细胞已首先进行临床测试，但骨髓基质干细胞和造血干细胞可能是一个有趣的替代选择，在选择的情况下，因为他们的自体来源和他们声称的可塑性。然而，仍有几个关键问题需要解决，包括（1）最佳细胞类型，（2）细胞移植改善心脏功能的机制，即，增加收缩力或限制重塑，（3）优化细胞存活的最有效策略，和（4）细胞移植在非缺血性心力衰竭中的潜在益处。与旨在解决这些问题的实验研究平行，初步临床试验正在进行中，希望能够了解细胞治疗所带来的希望是否能通过严重左心室缺血性功能障碍患者的功能和结局的临床有意义的改善来实现。
Cell transplantation is emerging as a new treatment designed tot improve the poor outcome of patients with cardiac failure. Its rationale is that implantation of contractile cells into postinfarction scars can functionally rejuvenate these areas. Primarily for practical reasons, autologous skeletal myoblasts have been the first to be tested clinically but bone marrow stromal and hematopoietic stem cells may represent an interesting alternative in select situations because of their autologous origin and their purported plasticity. However, several key issues still need to be addressed including (1) the optimal type of cells, (2) the mechanism by which cell engraftment improves cardiac function, i.e., increased contractility or limitation of remodeling, (3) the most effective strategies for optimizing cell survival, and (4) the potential benefits of cell transplantation in nonischemic heart failure. In parallel to the experimental studies designed to address these issues, initial clinical trials are underway and should hopefully allow to know whether the hopes raised by cellular therapy are met by clinically meaningful improvements in function and outcome in patients with severe left ventricular ischemic dysfunction.
登录
查看更多内容
骨骼肌和心肌之间的机电耦合。对梗塞修复的影响。
影响因子：
7.8
作者：
Reinecke, H;MacDonald, G H;Hauschka, S D;Murry, C E
通讯作者：
Murry, C E
影响因子：
5
作者：
Zhang, M;Methot, D;Murry, CE
通讯作者：
Murry, CE
影响因子：
15.9
作者：
Murry, CE;Wiseman, RW;Hauschka, SD
通讯作者：
Hauschka, SD
DOI：
10.1073/pnas.95.15.8801
发表时间：
1998-07-21
影响因子：
11.1
作者：
Kajstura, J;Leri, A;Anversa, P
通讯作者：
Anversa, P